amifampridine has been researched along with Disease Exacerbation in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Natera-de Benito, D | 1 |
| Bestué, M | 1 |
| Vilchez, JJ | 1 |
| Evangelista, T | 1 |
| Töpf, A | 1 |
| García-Ribes, A | 1 |
| Trujillo-Tiebas, MJ | 1 |
| García-Hoyos, M | 1 |
| Ortez, C | 1 |
| Camacho, A | 1 |
| Jiménez, E | 1 |
| Dusl, M | 1 |
| Abicht, A | 1 |
| Lochmüller, H | 1 |
| Colomer, J | 1 |
| Nascimento, A | 1 |
1 other study available for amifampridine and Disease Exacerbation
| Article | Year |
|---|---|
Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations.
Topics: 4-Aminopyridine; Adolescent; Adult; Amifampridine; Child; Child, Preschool; Cholinesterase Inhibitor | 2016 |